Catalyst
Slingshot members are tracking this event:
In February 2017, the data safety monitoring board recommended that FibroGen (FGEN) continue its Phase 3 roxadustat (FG-4592) programs
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 28, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Roxadustat, Independent Data Safety Monitoring Board, Fg-4592
